Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioadaptives (BDPT) EBITDA Margin (2019 - 2025)

Bioadaptives' EBITDA Margin history spans 7 years, with the latest figure at 5735.95% for Q3 2025.

  • For Q3 2025, EBITDA Margin changed N/A year-over-year to 5735.95%; the TTM value through Sep 2025 reached 14410.84%, down 1276748.0%, while the annual FY2024 figure was 4752.47%, 395106.0% down from the prior year.
  • EBITDA Margin for Q3 2025 was 5735.95% at Bioadaptives, up from 8674.09% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 415.47% in Q1 2024 and bottomed at 13774.52% in Q2 2024.
  • The 5-year median for EBITDA Margin is 2770.7% (2022), against an average of 3514.14%.
  • The largest annual shift saw EBITDA Margin tumbled -1138251bps in 2024 before it skyrocketed 510043bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 4615.27% in 2021, then skyrocketed by 85bps to 685.29% in 2022, then fell by -25bps to 857.99% in 2023, then crashed by -1505bps to 13774.52% in 2024, then skyrocketed by 58bps to 5735.95% in 2025.
  • Per Business Quant, the three most recent readings for BDPT's EBITDA Margin are 5735.95% (Q3 2025), 8674.09% (Q2 2025), and 13774.52% (Q2 2024).